Reply to In response to "Factors associated with the development of gastrointestinal adverse events in dogs with multicentric lymphoma treated with CHOP or CEOP-based protocols: a multi-institutional, retrospective study".

Doxorubicin is linked to a higher incidence of GI adverse events than epirubicin in canine lymphoma treatment.

A multi-institutional, retrospective study involving 178 dogs with multicentric lymphoma treated with CHOP or CEOP protocols investigated the incidence of gastrointestinal (GI) adverse events associated with anthracycline chemotherapy agents, specifically doxorubicin and epirubicin. Of the total cohort, 114 dogs (64.1%) received epirubicin, and 64 dogs (35.9%) received doxorubicin. GI adverse events were observed in 46 dogs (40.3%) in the epirubicin group and 36 dogs (56.2%) in the doxorubicin group. Statistical analysis revealed that male neutered dogs, those younger than 10 to 15 years, receiving epirubicin at a dosage of 1 mg/kg, and those with stage V disease were at a higher risk of developing GI adverse events. The study concluded that doxorubicin was associated with a higher incidence of GI adverse events compared to epirubicin in this canine lymphoma cohort. The authors suggested that these findings could inform clinical decisions regarding anthracycline selection to minimize side effects, although they emphasized the need for further prospective studies to definitively determine the optimal anthracycline choice. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40320245/?utm_source=openai))

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.